#United States #New York #Levi & Korsinsky #Regeneron Pharmaceuticals #SEC violations

Regeneron Pharmaceuticals Faces Class Action Lawsuit

On February 11, 2025, Levi & Korsinsky, LLP announced significant developments regarding Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), as they filed a class action lawsuit centered on allegations of securities law violations. This lawsuit seeks to hold the company accountable for various misleading practices that reportedly impacted investors negatively between November 2, 2023, and October 30, 2024.

Overview of Allegations

The core of the complaint suggests that Regeneron engaged in deceptive practices that inflated the sales figures of their significant product, Eylea. Specifically, the lawsuit claims that Regeneron made false statements and concealed several critical facts:

1. Payment of Credit Card Fees: It is alleged that Regeneron paid credit card fees to distributors under the condition that these distributors would not charge customers more when purchasing Eylea with credit cards.
2. Price Subsidies: The payments made by Regeneron inadvertently subsidized the prices that customers faced when they used credit cards for Eylea purchases.
3. Lowering of Selling Price: As a result of these practices, Regeneron offered price concessions that reduced Eylea's selling price.
4. Market Sensitivity: Since retina practices are sensitive to higher prices, these price reductions allegedly provided Regeneron with a competitive edge.
5. Misleading Sales Reports: Claims also include accusations that Regeneron’s actions contributed to inaccurately high reported sales of Eylea, misleading investors about the company’s financial health.
6. Violation of the False Claims Act: By not reporting these credit card fee payments as price concessions, Regeneron supposedly overstated the Average Sales Price (ASP) reported to federal agencies, which is a violation of the False Claims Act.
7. Misleading Statements: The combination of these actions is said to have rendered the company's positive announcements regarding its business and prospects materially misleading or without a reasonable basis.

Class Action Participation

Investors who experienced losses due to these alleged activities are encouraged to act promptly, as the deadline to moves the Court for lead plaintiff is March 10, 2025. Those affected do not need to be the lead plaintiff to participate in any recovered compensation.

No Cost Participation

Levi & Korsinsky emphasizes that class members may be entitled to compensation with no out-of-pocket costs or fees. Interested investors can obtain more information about the lawsuit and find a submission form through the link provided by Levi & Korsinsky.

Why Choose Levi & Korsinsky?

Over the past two decades, the legal team at Levi & Korsinsky has proven their expertise in securities litigation, securing substantial recoveries for aggrieved shareholders. With a robust team of over 70 professionals, the firm is well-equipped to navigate complex legal landscapes. They have consistently been ranked among the top securities litigation firms in the U.S. by ISS Securities Class Action Services.

For further inquiries, investors can contact Joseph E. Levi, Esq. or Ed Korsinsky, Esq. directly via email or telephone. The firm offices are located at 33 Whitehall Street, 17th Floor, New York, NY 10004.

As the situation continues to evolve, it remains crucial for investors to stay informed and consider their options carefully amidst these developments surrounding Regeneron Pharmaceuticals.